Navigation Links
Immunosyn Corporation to Present at FSX
Date:10/24/2007

LA JOLLA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- Immunosyn Corporation's (OTC Bulletin Board: IMYN) CEO, Stephen Ferrone, will make a presentation to brokers and financial institutions at the Financial Services Exchange (FSX) Investment Conference at the Pointe South Mountain Resort in Phoenix, AZ on Thursday, October 25, 2007.

Immunosyn has obtained exclusive worldwide marketing, sales and distribution rights to SF-1019 from its largest shareholder, Argyll Biotechnologies, LLC. Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. The company went public in January of this year and its stock will begin trading on Friday, October 26, 2007.

"Immunosyn is privileged to present to the elite group of brokers and dealers at FSX. We look forward to communicating our company's objectives and overview as well as to answering questions," noted Ferrone.

FSX is a premier investment conference organization attended by independent NASD broker/dealer firms. For more than 20 years, FSX has brought these firms together for the purpose of sharing information and showcasing investment opportunities.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.

FOR FURTHER INFORMATION, CONTACT: Bill Kraus/Lisa Baker/Devon Blaine

The Blaine Group

310/360-1499

310/360-1498 (FAX)

blaine@blainegroupinc.com


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
11. Wisconsin firms to present at Cleantech venture capital event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)...   ViaCyte, Inc ., a leading, privately-held ... cell-derived islet replacement therapy for the treatment of ... that ViaCyte and Janssen Biotech, Inc., one of ... have agreed to consolidate the assets of the ... ViaCyte with an exclusive license to all BetaLogics ...
(Date:2/3/2016)... BRUNSWICK, N.J. , Feb. 3, 2016 /PRNewswire-USNewswire/ ... grants totaling more than $1 million for researchers ... are working on health-related research that demonstrates exciting ... this round of funding for the New Jersey ... for faculty members at these educational institutions— Princeton ...
(Date:2/3/2016)... MEDFORD, Mass. , Feb. 3, 2016  Silk Therapeutics, ... A2 financing round. Silk Therapeutics has now raised a total ... progress made by the company. The Series A2 round was ... Foxboro, Massachusetts , with participation from new investors Lear ... Sheri and Roy P. Disney ; Richard Sackler ...
(Date:2/3/2016)... ... February 03, 2016 , ... Big games come and go, but ... much for our country. CereScan, a nationally recognized brain diagnostics and technology company, will ... Football Team (WWAFT) vs. NFL Stars Flag Football Game on February 6, 2016. ...
Breaking Biology Technology:
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016 ... innovative sensor-based diagnostic products, today announced the closing of a ... existing investors.  Proceeds from the financing will be used to ... hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction has ...
(Date:1/7/2016)... , Jan. 7, 2016 This BCC Research ... for biometric technologies and devices, identifying newer markets and ... various types of biometric devices. Includes forecast from 2015 ... Identify newer markets and explore the expansion of the ... Examine each type of biometric technology, determine its current ...
(Date:1/7/2016)... -- A United States District Court in Illinois ... to interpret a biometric privacy statute in a decision ... photo website Shutterfly brought by the law firm Carey Rodriguez ... SHUTTERFLY, INC.; and THISLIFE, INC ( N.D. Ill ., ... Illinois Biometric Privacy Act by collecting and scanning face ...
Breaking Biology News(10 mins):